Maurizio Belfiglio
Overview
Explore the profile of Maurizio Belfiglio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marconi P, Zappala C, Lofaro A, Maiolino S, Mastellone C, Belfiglio M
Recenti Prog Med
. 2022 Jul;
113(7):451-459.
PMID: 35852081
Introduction: Rare diseases have a high social and health impact. Since 2005, AIFA has been funding independent clinical research. The objective of this paper is to describe data on independent...
2.
Mozzi A, Meregaglia M, Lazzaro C, Tornatore V, Belfiglio M, Fattore G
Clinicoecon Outcomes Res
. 2016 Jul;
8:267-74.
PMID: 27358571
Weights associated with the EuroQol 5-Dimension 3-Level (EQ-5D-3L) instrument represent preferences for health states elicited from general population's samples. Weights have not been calculated for every country; however, empirical research...
3.
Belfiglio M, Sichetti D, Romero M, Orsini A
Recenti Prog Med
. 2013 Jun;
104(6):241-5.
PMID: 23801227
Introduction: The unmet therapeutic needs lead to accelerated registration of new oncology drugs, even with incomplete information of the benefit-risk ratio. Methods: In Italy the Onco-AIFA Register was established to...
4.
Scurti V, Di Ienno S, Fanizza C, Belfiglio M, DEttorre A, Romero M, et al.
Tumori
. 2012 Apr;
98(1):19-26.
PMID: 22495697
Aims And Background: Cancer in young patients (15-39 years) is unique for the distribution of types, therapeutic options and clinical evolution. Administrative databases represent well-documented tools in epidemiology, and in...
5.
Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C
J Cancer Res Clin Oncol
. 2011 Nov;
138(2):221-9.
PMID: 22095437
Purpose: Whether combination chemotherapy offers an advantage over sequential therapy in metastatic breast cancer (MBC) is still an unsettled issue. Polychemotherapy regimens containing taxanes has been shown to increase overall...
6.
Cioffi P, Laudadio L, Nuzzo A, Belfiglio M, Petrelli F, Grappasonni I
J Oncol Pharm Pract
. 2011 Nov;
18(2):299-302.
PMID: 22065198
Gemcitabine is a commonly used chemotherapeutic agent for a variety of tumors. Although this nucleoside analog antineoplastic agent is similar in structure to cytarabine, central nervous system toxicities have rarely...
7.
Cioffi P, Antonelli D, Belfiglio M, Melena S, Petrelli F, Grappasonni I
J Oncol Pharm Pract
. 2011 Oct;
18(2):207-12.
PMID: 22020659
Aims And Background: At the Oncology Department of the Chieti and Ortona Hospitals, the pharmacist designated by the Abruzzo Region to oversee the obligatory monitoring of innovative oncological drugs listed...
8.
Genovesi D, Ausili Cefaro G, Vinciguerra A, Augurio A, DI Tommaso M, Marchese R, et al.
Strahlenther Onkol
. 2011 May;
187(6):357-66.
PMID: 21603989
Background: To determine interobserver variability in clinical target volume (CTV) of supra-diaphragmatic Hodgkin's lymphoma. Materials And Methods: At the 2008 AIRO (Italian Society of Radiation Oncology) Meeting, the Radiation Oncology...
9.
Verderio P, Mangia A, Orlando C, Belfiglio M, Marchetti A, Bertario L, et al.
Tumori
. 2011 Feb;
96(5):721-5.
PMID: 21302619
Aims And Background: In 2007, an Italian Research Network proposed to the Ministry of Health a concerted action aimed at developing a specific pathway for the analytical and clinical validation...
10.
Mandala M, Imberti G, Piazzalunga D, Belfiglio M, Lucisano G, Labianca R, et al.
Mayo Clin Proc
. 2011 Feb;
86(2):113-9.
PMID: 21282485
Objective: To investigate the influence of socioeconomic status (SES) on Breslow thickness, disease-free survival, and overall survival in patients with stage I-II primary cutaneous melanoma (PCM). Patients And Methods: The...